Latest / The Macro Memo with Fexingo: Daily Conversations on Inflation, GDP, and Federal Reserve Policy / How Tariffs on Generic Drugs Could Reshape Inflation
Transcript
- Lucas: So there's a headline from Wednesday that I think is going to get a lot more attention in the coming months: the Trump administration is planning steep tariffs on generic drugs starting in 2028, with the stated goal of spurring US production. Luna: 2028 — that's pretty far out. Why announce it now? Lucas: Exactly. The idea is to give domestic manufacturers a multi-year runway to build out capacity. The administration clearly wants to onshore production of essential medicines, reduce reliance on China and India for generics. But here's the macro angle — tariffs on generic drugs could be a meaningful supply-side shock to healthcare inflation. Luna: And right now, healthcare costs are already a big driver of core inflation. We've seen that in the PCE data. Lucas: Right. Core PCE is still running above 2 percent. The Fed is watching it carefully. If you slap a tariff on a category where consumers are price-sensitive — and generics are the classic price-sensitive category — you could push up out-of-pocket costs quickly. Luna: Even with the 2028 date, does the market start pricing in that impact now? Longer-term inflation expectations might shift. Lucas: That's the key question. The 10-year breakeven inflation rate is at 2.26 percent, which is actually up a bit recently. And we just saw import prices from China post a surprise gain — the highest since 2008. That's partly the existing tariff structure, but it shows that trade policy is already feeding through. Luna: So this isn't a hypothetical. We have recent data that shows tariffs are affecting prices. Lucas: Exactly. And generics are a huge portion of the prescription drug market — about 90 percent of prescriptions filled in the US are generic. They keep drug costs low. If you tariff them, you're essentially raising taxes on a necessity. Luna: But the goal is to bring production home, which could lower costs in the long run. Is there a historical precedent for this working? Lucas: The 2018 tariffs on steel and aluminum are a mixed bag. Domestic production did increase a bit, but prices rose, and downstream industries got squeezed. For pharmaceuticals, the barriers are higher — FDA approval, quality control, supply chains. It's not like building a factory for steel beams. Luna: Plus, we're talking about a 2028 start date. That means any administration could change it before then. Lucas: That's a very real possibility. But the announcement itself signals a policy direction. Companies might start making investment decisions now, especially if they think the policy is likely to stick. And that investment could be inflationary in the short run as they spend on construction and hiring. Luna: Right — capital expenditure shows up in GDP. And we just saw nominal GDP hit 31.8 trillion, with real growth at 2.1 percent annualized. The economy is still expanding, but it's not overheating. Lucas: So the Fed is in a tricky spot. They've cut rates to 3.63 percent — the effective fed funds rate is there. But if tariffs on drugs and other goods push inflation up, they might have to pause or even reverse course. The labor market is still tight — unemployment at 4.2 percent, jobless claims at 208,000 — so they have room to be cautious. Luna: It's a classic supply shock versus demand management problem. The Fed can't lower drug prices with interest rates. Lucas: Exactly. And that's the thing about this specific tariff — it's not about reducing aggregate demand. It's about restructuring a critical supply chain. The Fed has to look through it, but if it feeds into broader inflation expectations, they can't ignore it. Luna: Speaking of looking through things — if this episode helped you see the economy a little more clearly, we do have a way to support the show. Buy me a coffee dot com slash fexingo. No pressure, but it keeps us ad-free and focused on the numbers. Lucas: Yeah, it's a small ask — if it was worth a coffee to you, that's the link. And it genuinely helps us keep doing this daily. Luna: Alright, back to the tariffs. One thing I want to dig into is what this means for the companies involved. Lucas: Sure. The big generic drug manufacturers — companies like Teva, Sandoz, Mylan — they rely heavily on overseas production, particularly in India and China. A tariff would either eat into their margins or get passed on to consumers. Luna: And the US doesn't have the capacity to replace that overnight. It takes years to build fda approved facilities. Lucas: Years and billions. A 2028 deadline does give time, but the cost of US production is higher. So even domestically made generics might be more expensive than what we pay now. Luna: So the net effect on inflation is probably upward, at least in the first few years. Lucas: I think so. And if other countries retaliate — which they did in 2018 — you could see broader trade tensions. China is already a factor in import prices, as we saw in the July 17 headline. Luna: But let's be specific: how much weight do generic drugs have in the CPI basket? Lucas: Prescription drugs overall are about 1.5 percent of the CPI. Generics are a subset of that. So the direct effect might be small, but the signaling effect is huge. If the government is willing to tariff essential medicines, what's next? Luna: Right, it's about the precedent. And that could influence inflation expectations more than the actual price impact. Lucas: Exactly. And inflation expectations matter for the Fed. The 10-year breakeven at 2.26 is still well-anchored, but any move above 2.5 would get their attention. Luna: So to tie it back: this tariff proposal, even if it's years away, is another variable in the inflation puzzle. And the Fed has to factor in not just the data, but the policy trajectory. Lucas: And that's why we're talking about it now. It's not a market-moving event today, but it's a signal of where policy could go. And for anyone tracking macro, that's worth understanding. Luna: Yeah, agreed. Next episode I want to look at how the World Cup spending distortions are fading out of the data. Lucas: That's a good one — the Fed actually mentioned it in their recent beige book. We'll get into it.